Celsion (NASDAQ:CLSN) Upgraded to “Hold” by ValuEngine

Celsion (NASDAQ:CLSN) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, ValuEngine reports.

A number of other brokerages also recently issued reports on CLSN. Zacks Investment Research raised shares of Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Brookline Capital Management reissued a “buy” rating on shares of Celsion in a report on Thursday, July 25th.

NASDAQ CLSN traded up $0.03 during trading on Thursday, hitting $1.74. 93,007 shares of the company’s stock traded hands, compared to its average volume of 82,229. The stock has a market capitalization of $35.85 million, a PE ratio of -2.56 and a beta of 1.94. Celsion has a 12-month low of $1.35 and a 12-month high of $3.10. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 0.51. The business’s 50 day simple moving average is $1.78.

Celsion (NASDAQ:CLSN) last released its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative net margin of 1,954.60% and a negative return on equity of 65.35%. On average, research analysts expect that Celsion will post -1.13 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Celsion stock. BlackRock Inc. boosted its stake in Celsion Co. (NASDAQ:CLSN) by 21.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,426 shares of the biotechnology company’s stock after purchasing an additional 25,548 shares during the quarter. BlackRock Inc. owned about 0.76% of Celsion worth $202,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 4.76% of the stock is currently owned by institutional investors.

Celsion Company Profile

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Recommended Story: Diversification Important in Investing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.